

## The Flagship Antibody-Drug Conjugate Event is Back! – World ADC Asia 2024

26 April 2024 | News

**The wait is finally over and by popular demand, the leading ADC industry touchpoint is heading to Asia again this Summer!**

image not found or type unknown



With a storm of collaborations and novel innovations happening, all eyes are turning towards the APAC region for the next best thing when it comes to antibody-drug conjugate development. The 3rd World ADC Asia (June 25-27, 2024 |Incheon, South Korea) is back to unite the growing community of Asian-based drug developers.

The 3-day agenda has been designed to allow insightful discussions into your most pressing challenges, novel payloads, identifying unique targets, stable linker chemistries, working through manufacturing and regulatory hurdles, and more to boost ADC development and innovation.

**[Get the full agenda here.](#)**

This conference will host 150+ experts of the ADC community in Asia sharing their views, with a total of 20+ keynote presentations and 2 exciting workshops.

**Official Speaker Faculty**

With a stellar lineup of 25+ industry-leading speakers from within Asia, here is a snapshot of who you could meet this June:

1. Jinwon Jung, Senior Director, ABL Bio
2. Dohyun Nam, Chairman, Aimed Bio
3. Ziping Wei, Chief Executive Officer, Bliss Biopharma
4. Yasuyuki Kaneta, Senior Director, Daiichi Sankyo
5. Masayuki Miyano, Principal Scientist, Eisai
6. Jun Ge, Executive Director, Head of China Clinical Development, Gilead
7. Tse Wen Chang, Founder & Chairman, Immunwork
8. Sun-Hwa Lee, Chief Scientific Officer, Novelty Nobility
9. Heidi Wang, Chief Executive Officer, OBI Pharma
10. Hyun Yong Cho, Chief Scientific Officer, PinotBio

**[See the full speaker faculty and session details here.](#)**

**Top Sessions**

**Workshop Day – 06/25**

1. Navigating Varying Regulatory Guidance to Inform ADC Clinical Studies & Meet Global Regulatory Requirements
2. Navigating Strategic Collaborations to Make a Mark in the ADC World

**Conference Day One – 06/26**

1. Outlining Clinical Updates & Clinical Progression in Field to Ensure a Smooth Translation Into the Clinic
2. Honing Novel Innovations in ADC Technologies Coming Out of Asia to Establish Competitive Differentiation
3. Exploring Global Manufacturing Capabilities & the Challenges With Antibody & Linker-Payload Supply Chain to Reduce Process Complexity & Standardize ADC Development

**Conference Day Two – 06/27**

1. Identifying Novel Targets & Their Benefits to Diversify ADC Programs & Design a More Accurate ADC
2. Innovating Novel Linker & Payload Technologies to Increase Stability, Efficiency & Patient Treatability
3. Maximizing Therapeutic Window to Increase Efficacy & Reduce Off Target Toxicity of ADC

We find ourselves at the cutting edge of oncology innovation, with the field booming with excitement due to the constant efflux of clinical progress and a plethora of high-value collaborations.

**[Book your place today!](#)** Early registration and group discounts available.

For more information about World ADC Asia please visit: [www.worldadc-asia.com](http://www.worldadc-asia.com)

**About the Organizer**

Backed by almost 15 years of experience providing insights to the global community, World ADC is the perfect opportunity to gain unbiased insights and meet the pioneers in the space who are propelling innovation in the region and accelerating antibody-drug conjugates to approval. World ADC is part of Hanson Wade Limited Group. Based in the UK, Hanson Wade Conferences improve drug development decision-making to accelerate safer, more effective, and accessible drugs to patients in need. We provide biopharmaceutical leaders unrivalled access to premium content and insight. Critical information, delivered by world-class industry speakers to progress the right targeted therapies to the right patients, faster.

**For More Information please contact:**

Jessica Durston

Marketing Manager – World ADC Team Hanson Wade

[adc@hansonwade.com](mailto:adc@hansonwade.com)